Scarica l'app Stockscreener
6.57
3.24%
-0.22
Pre-mercato:
6.70
0.13
+1.98%
Lexeo Therapeutics Inc Borsa (LXEO) Ultime notizie
Quarterly Risk: Is Lexeo Therapeutics Inc forming a bullish divergence2025 Support & Resistance & Free High Accuracy Swing Entry Alerts - baoquankhu1.vn
Volatility Watch: Is Lexeo Therapeutics Inc backed by strong institutional buyingPortfolio Return Report & Low Risk High Reward Ideas - baoquankhu1.vn
Lexeo Therapeutics Announces Head of Research Transition - The Globe and Mail
Lexeo Therapeutics to Participate in Upcoming Investor Conferences in February - 富途牛牛
Biotech Lexeo to stream Feb investor talks from New York and online - Stock Titan
H.C. Wainwright Says Market Remains Unconvinced on Lexeo Therapeutics, Inc. (LXEO)’s PKP2 Program - Yahoo Finance
H.C. Wainwright Says Market Remains Unconvinced on Lexeo Therapeutics, Inc. (LXEO)'s PKP2 Program - Finviz
Lexeo TherapeuticsRevolutionizing Heart Health With Gene Therapies - RTTNews
Lexeo Therapeutics Announces Key Executive Leadership Changes - The Globe and Mail
Lexeo Therapeutics Announces Key Leadership Appointments - citybiz
Lexeo Therapeutics appoints new COO and CMO, announces executive transition - Investing.com Nigeria
Lexeo Therapeutics appoints new COO and CMO, announces executive transition By Investing.com - Investing.com South Africa
Lexeo Therapeutics Announces Executive Appointments - marketscreener.com
Lexeo Therapeutics Announces Key Executive Appointments - TradingView
Lexeo appoints Jose Manuel Otero as COO - TipRanks
Lexeo Therapeutics announces key leadership appointments By Investing.com - Investing.com Nigeria
Lexeo Therapeutics announces key leadership appointments - Investing.com
Lexeo Therapeutics Announces Key Leadership Appointments Strengthening Cardiovascular Expertise Alongside Updates to Strategic Partnership for Novel Cardiac RNA Therapeutics - The Manila Times
Lexeo Therapeutics Announces Key Leadership Appointments to Drive Advances in Cardiovascular Medicine - Quiver Quantitative
New cardiology leaders join Lexeo as it backs novel cardiac RNA startup - stocktitan.net
Investor Mood: Can Lexeo Therapeutics Inc be the next market leaderJuly 2025 Snapshot & AI Powered Market Entry Ideas - baoquankhu1.vn
Financial Analysis: Esperion Therapeutics (NASDAQ:ESPR) & Lexeo Therapeutics (NASDAQ:LXEO) - Defense World
Lexeo Therapeutics, Inc. (NASDAQ:LXEO) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
Weekly Trades: Whats next for Lexeo Therapeutics Inc stockJuly 2025 Setups & Advanced Swing Trade Entry Alerts - baoquankhu1.vn
Volume Recap: Is Bassett Furniture Industries Incorporated stock technically oversoldWeekly Trade Report & Fast Momentum Stock Entry Tips - baoquankhu1.vn
Fund Flows: What is GNSRTs debt to equity ratioWeekly Trend Summary & Precise Trade Entry Recommendations - baoquankhu1.vn
Market Wrap: Can Lexeo Therapeutics Inc ride the EV waveJuly 2025 Setups & Daily Technical Forecast Reports - baoquankhu1.vn
Technical Analysis: Is Lexeo Therapeutics Inc subject to activist investor interestJuly 2025 Macro Moves & Safe Entry Trade Reports - baoquankhu1.vn
Block Trades: Does Lexeo Therapeutics Inc have a sustainable dividend2025 Risk Factors & Real-Time Volume Spike Alerts - baoquankhu1.vn
Does Lexeo Therapeutics Inc have a sustainable dividendPortfolio Value Summary & Low Risk High Win Rate Picks - baoquankhu1.vn
Lexeo Therapeutics Stock Rallies On Discussions With FDA To Expedite Friedreich’s Ataxia Drug Approval Process - MSN
Lexeo Therapeutics price target lowered to $10 from $13 at H.C. Wainwright - TipRanks
Aug Update: Is SLAB subject to activist investor interestWeekly Investment Recap & Real-Time Stock Entry Alerts - baoquankhu1.vn
Aug Decliners: Will Lexeo Therapeutics Inc outperform its industry peersEarnings Risk Report & Weekly Top Gainers Trade List - baoquankhu1.vn
Price Action: Will Lexeo Therapeutics Inc outperform its industry peersAnalyst Upgrade & Fast Moving Stock Watchlists - baoquankhu1.vn
LXEO: Cardiac gene therapy programs show strong efficacy, safety, and commercial readiness - TradingView — Track All Markets
Heart-disease gene therapy race heating up as Lexeo posts data - BioWorld MedTech
Lexeo Therapeutics stock falls 23% despite Cantor maintaining Overweight rating - Investing.com Canada
Lexeo Therapeutics (NASDAQ:LXEO) Trading Down 6.5%Should You Sell? - MarketBeat
Day Trade: Will Lexeo Therapeutics Inc stock outperform growth indexesJuly 2025 Setups & Safe Entry Point Alerts - Bộ Nội Vụ
H.C. Wainwright lowers Lexeo Therapeutics stock price target on PKP2 data concerns - Investing.com Canada
Oppenheimer reiterates Outperform rating on Lexeo Therapeutics stock By Investing.com - Investing.com Canada
Aug Intraday: Will Lexeo Therapeutics Inc. stock deliver shareholder valueJuly 2025 Price Swings & Stepwise Trade Signal Guides - Bộ Nội Vụ
Oppenheimer reiterates Outperform rating on Lexeo Therapeutics stock - Investing.com
Lexeo Therapeutics (NASDAQ:LXEO) Given "Buy" Rating at Chardan Capital - MarketBeat
Lexeo’s gene therapy shows promising results for heart condition By Investing.com - Investing.com Nigeria
Lexeo Therapeutics Reflects Structural Trends In Clinical Biotech - Kalkine Media
Lexeo Therapeutics (NASDAQ:LXEO) Shares Gap DownHere's What Happened - MarketBeat
Gold Rises Sharply; Lyra Therapeutics Shares Plunge - Benzinga
Lexeo Therapeutics Reports Positive Interim HEROIC-PKP2 Trial Results - TipRanks
Lexeo Therapeutics Announces Positive Interim Phase I/II Data for LX2020 - TradingView — Track All Markets
Lexeo Therapeutics stock falls after PKP2 gene therapy data By Investing.com - Investing.com Canada
Lexeo Therapeutics stock falls after PKP2 gene therapy data - Investing.com
1.24%
0.19%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):